Epizyme To Present Data From The Tazemetostat Non-Hodgkin Lymphoma Program At American Society for Hematology Meeting on Lymphoma Biology

CAMBRIDGE--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that data from four abstracts from the Company’s clinical development program in support of tazemetostat for use in non-Hodgkin lymphoma (NHL) will be presented during the American Society of Hematology Meeting on Lymphoma Biology, to be held in Colorado Springs, CO, from June 18 to June 21, 2016.